CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Operating activities:
Net loss	$ (7,988,323)	$ (9,129,756)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	1,984,139	1,949,845
Depreciation-Right of Use Assets - Financing	77,790	73,313
Stock based compensation	1,471,683	1,890,991
Derecognition of contingency and grant	0	(10,000)
Amortization of financing fees	5,833	2,500
Provision (recovery) of doubtful accounts	747,772	259,576
Loss (gain) on marketable securities	(14,418)	401,336
Stock warrant expense	(8,130)	28,477
Change in operating assets and liabilities:
Accounts receivable	212,393	(550,866)
Referral and support services agreement advance	225,000	225,000
Prepaid expenses, other current assets and other assets	(172,679)	316,053
Accrued expenses and other liabilities	3,279,560	916,363
Accounts payable	(278,336)	806,824
Net cash used in operating activities	(457,716)	(2,820,344)
Investing activities:
Purchases of equipment and capitalized development costs	(1,259,217)	(1,311,315)
Purchase of marketable securities	0	(1,693,963)
Proceeds from the sale of marketable securities	2,288,873	1,403,282
Net cash provided by (used in) investing activities	1,029,656	(1,601,996)
Financing activities:
Gross proceeds from line of credit	592,868	0
Repayments on line of credit	(592,868)	0
Payments on finance lease obligations	(84,138)	(75,848)
Proceeds from at-the-market sales	61,136	0
Capital raise, net of issuance costs	3,665,000	0
Net taxes paid on restricted stock unit grants exercised	(166,872)	(196,894)
Net cash provided by/(used in) financing activities	3,475,126	(272,742)
Net change – cash	4,047,066	(4,695,082)
Cash and cash equivalent, beginning of year	2,931,415	10,475,964
Cash and cash equivalent, end of period	6,978,481	5,780,882
Supplemental information:
Interest paid	85,488	15,128
Acquisition of right of use asset for operating lease liability	$ 1,105,148	$ 0